Screener
Ultragenyx Pharmaceutical RARE Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333233
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Research and development | 167 | 165 | 354 | 331 |
| Selling, general and administrative | 88 | 87 | 176 | 174 |
| Total operating expenses | 289 | 275 | 594 | 557 |
| Loss from operations | (75) | (108) | (244) | (251) |
| Interest income | 5 | 6 | 11 | 13 |
| Non-cash interest expense on liabilities for sales of future royalties | (22) | (14) | (43) | (28) |
| Other income | 1 | 2 | 1 | 2 |
| Loss before income taxes | (91) | (114) | (275) | (264) |
Item 1. Financial Statements
FAQ
- What is Ultragenyx Pharmaceutical's operating income?
- Ultragenyx Pharmaceutical (RARE) reported operating income of -$75M in Q2 2026.
- How has Ultragenyx Pharmaceutical's operating income changed year-over-year?
- Ultragenyx Pharmaceutical's operating income increased by 30.6% year-over-year, from -$108M to -$75M.
- What is the long-term trend for Ultragenyx Pharmaceutical's operating income?
- Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's operating income has grown at a 8.8% compound annual growth rate (CAGR), from -$381.74M to -$535.17M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Ultragenyx Pharmaceutical's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude